The US FDA has approved guselkumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis (PsA) in children aged 6 years or older who weigh at least 40 kg, according ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results